attention-deficit hyperactivity disorder
Neurology · 2005–2008
2decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| atomoxetine hydrochloride Initial and continuing treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician… | Jul 2008 | Recommended with restriction | no section in document |
| atomoxetine hydrochloride Initial treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between ages 6 and 18 years in patients unable to take dexamphetamine sulfate or… | Nov 2005 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.